Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies

Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study

(2023) Teresa A Simon et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis

(2021) Ruolin Liu et al.   Cancer Cell International

Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis

(2018) Hermine I. Brunner et al.   Arthritis & Rheumatology

Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study

(2018) François Montastruc et al.   RHEUMATOLOGY

Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice

(2017) Hjalmar Wadström et al.   JAMA Internal Medicine

Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study

(2016) Eva Lange et al.   RHEUMATOLOGY

Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden

(2016) Pauline Raaschou et al.   BMJ-British Medical Journal

Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden

(2016) Pauline Raaschou et al.   BMJ-British Medical Journal

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

(2015) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

(2014) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Smoking and Rheumatoid Arthritis

(2014) Kathleen Chang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs

(2013) Daniel H. Solomon et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register

(2012) Louise K Mercer et al.   ANNALS OF THE RHEUMATIC DISEASES

The origins, function, and regulation of T follicular helper cells

(2012) Cindy S. Ma et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

(2011) J. M. Kremer et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis

(2011) Wassila Amari et al.   RHEUMATOLOGY

Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

(2010) Philip Mease et al.   ARTHRITIS AND RHEUMATISM

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

(2010) Johan Askling et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

(2009) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment

(2008) T A Simon et al.   ANNALS OF THE RHEUMATIC DISEASES

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

(2008) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case–control study

(2008) AØ Jensen et al.   BRITISH JOURNAL OF CANCER

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

(2008) Nicolino Ruperto et al.   LANCET

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES